Xenon Pharmaceuticals Inc. (XENE)

Market Cap	3.05B
Revenue (ttm)	n/a
Net Income (ttm)	-213.39M
Shares Out	76.24M
EPS (ttm)	-2.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	324,060
Open	39.49
Previous Close	39.55
Day's Range	39.40 - 40.30
52-Week Range	35.53 - 50.99
Beta	1.21
Analysts	Strong Buy
Price Target	56.00 (+40.07%)
Earnings Date	Feb 27, 2025

About XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2014
• Employees: 259
• Stock Exchange: NASDAQ
• Ticker Symbol: XENE
• Website: https://www.xenon-pharma.com

Analyst Forecast

According to 7 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is $56.0, which is an increase of 40.07% from the latest price.

Price Target

$56.0

(40.07% upside)

Analyst Consensus: Strong Buy